GKCAS 2026 Annual Symposium
The Greater Kansas City Allergy Society (GKCAS) hosts an annual symposium to gather the providers, nurses, fellows and interested students and residents of the greater Kansas City area to provide education on the latest relevant topics in allergy and clinical immunology. The symposium provides didactic lectures by renowned experts on relevant topics.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS). The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 4 contact hours.
Commercial Support
This activity is supported in part by an independent medical education grant from Genentech, a member of the Roche Group.
Target Audience
Practicing allergists
Primary care physicians
Allied healthcare professionals
Learning Objectives
At the conclusion of this activity learners should be able to…
1. Diagnose food allergy using current evidence-based approaches, including component-resolved diagnostics, skin testing, and oral food challenges.
2. Compare and contrast available treatment options for food allergy, including OIT, SLIT, EPIT, and FDA-approved biologics, and identify appropriate candidates for each.
3. Describe the evidence supporting complementary and alternative medicine (CAM) modalities in allergic disease and counsel patients regarding their safety and efficacy.
4. Apply current consensus criteria for diagnosing mast cell activation syndrome and systemic mastocytosis.
5. Differentiate between primary, secondary, and idiopathic causes of mast cell activation and outline evidence-based management strategies.
6. Implement up-to-date protocols for evaluating and delabeling drug allergies, including risk stratification and direct oral challenge when appropriate.
7. Integrate new therapeutic and diagnostic advances into daily practice to improve patient outcomes and efficiency of allergy care.
8. Communicate more effectively with patients about novel treatment options and alternative approaches, fostering shared decision-making and patient trust.
9. Recognize and overcome barriers—such as payer restrictions or limited training—that impede adoption of modern allergy therapies.
10. Demonstrate increased confidence and competence in delivering comprehensive, individualized allergy management based on current evidence and best practices.
Greater Kansas City Allergy Society 2026 Annual Symposium
March 7, 2026
Intercontinental, Country Club Plaza, Kansas City
All CME sessions will be held in the Salon III
Exhibits will be available in the Salon II
8:20 - 8:50 am Registration and Vendor Exhibits
8:50 - 9:00 am Welcome and Introduction
9:00 - 9:50 am David Khan, M.D.: What’s New in Antibiotic Allergies?
9:50 - 10:00am Q&A
10:00am-10:50am Cem Akin, M.D., Ph.D.: Mast Cell Disorders
10:50-11:00am Q&A
11:00am-11:50am Matthew Greenhawt, M.D.: Treating IgE-Mediated Food Allergy
11:50 - 12:00pm Q&A
12:00 - 12:30pm Lunch and Vendor Exhibits
12:30 - 1:20pm Gary Soffer, M.D.: The Myth of the Boosted Immune System
1:20 - 1:30pm Q&A
1:30pm – 2:00pm Final Announcements and Adjournment
All relevant financial relationships with ineligible companies have been mitigated.
Alice Chou, MD, Planner
Researcher: Novartis
Brynn Everist, MD, Planner
Advisor: Sanofi
Speaker: Sanofi
Marissa Love, MD, Planner
Researcher: Teva, Target Pharma Solutions, AstraZeneca, Celldex, Allergy Therapeutics
Cem Akin, MD, PhD, Speaker
Consultant: Blueprint Medicine, Cogent, Telios, Novartis
Researcher: Blueprint Medicine, Cogent, Telios
Matthew Greenhawt, MD, Speaker
Consultant: Aquestive
Speaker: ARS, Genentech
Advisor: Nutricia, DBV, Novartis, Aquestive, Bryn, Genentech, Allergy Therapeutics, ALK-Abello
The following have no relevant financial relationships with ineligible companies to disclose:
Maggie Barnthouse, MD, Planner
Mary Jacobson, MD, Planner
David Khan, MD, Speaker
Gary Soffer, MD, Speaker
Available Credit
- 4.00 AMA PRA Category 1 Credit™
- 4.00 Attendance
- 4.00 CBRN

Facebook
X
LinkedIn
Forward